Around 40- 60% of the patients diagnosed with NSCLC develop BM during the course of their disease, and this cumulative risk increases up to 70% in patients with epidermal growth factor receptor (EGFR) mutation (4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.